Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PD”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMedDate not supplied

Glucose-6-phosphate dehydrogenase (G-6-PD) mutations in Mexico: four new G-6-PD variants.

Screening for mutations at the G-6-PD gene by PCR-SSCP combined with restriction enzyme analysis and DNA sequencing was performed in nine G-6-PD deficient individuals with negative results for the presence of the most frequent G-6-PD mutations previously observed in Mexican population. The variants G-6-PD Valladolid(406T), G-6-PD Durham(713G), and G-6-PD Viangchan(871A) and four new G-6-PD mutant alleles were identified. The new mutations are located at cDNA nt 376 A --> T (126 Asn --> Tyr), nt 770 G --> T (257 Arg --> Leu), nt 1094 G --> A (365 Arg --> His), and nt 1285 A --> G (429 Lys --> Glu) and they were named G-6-PD San Luis Potosi, G-6-PD Zacatecas, G-6-PD Veracruz, and G-6-PD Yucatán, respectively. To date, a total of 18 different G-6-PD variants have been observed in Mexico and several of them are common in Africa, South Europe, and Southeast Asia.

Base Sequence↗
PubMed2003

Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.

Interactions between CD8+ T cells and endothelial cells are important in both protective and pathologic immune responses. Endothelial cells regulate the recruitment of CD8+ T cells into tissues, and the activation of CD8+ T cells by antigen presentation and costimulatory signals. PD-L1 and PD-L2 are recently described B7-family molecules which bind to PD-1 on activated lymphocytes and down-regulate T cell activation. We found that PD-L1 is expressed on interferon-gamma stimulated cultured human and mouse endothelial cells, while PD-L2 was found on stimulated human but not mouse endothelial cells. Expression was further up-regulated by TNF-alpha. Antibody blockade of endothelial cell PD-L1 and PD-L2 enhanced endothelial cell costimulation of PHA-activated human CD8+ T cells. Antibody blockade of mouse endothelial cell PD-L1 enhanced both IFN-gamma secretion and cytolytic activity of CD8+ T cells in response to endothelial cell antigen presentation. These results show that IFN-gamma activated endothelial cells can inhibit T cell activation via expression of the immunoinhibitory PD-L1 and PD-L2 molecules. Endothelial expression of PD-ligands would allow activation and extravasation of T cells without excessive vessel damage. Our findings highlight a potentially important pathway by which endothelial cells down-regulate CD8+ T cell-mediated immune responses.

Animals↗
PubMed2005

PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion.

The B7 family member programmed death ligand 2 (PD-L2) has been implicated in both positive and negative regulation of T cell activity. In this study, we demonstrate that on human T cells, PD-L2 acts only as a negative regulator of T cell activity, inhibiting proliferation, IL-2 production, and IFN-gamma production via its interaction with programmed death-1 (PD-1). This study also shows a novel role for PD-1 in inhibiting beta1 and beta2 integrin-mediated adhesion. PD-L2 inhibition of T cell function involves modulation of the phosphoinositide 3-OH kinase (PI 3-K)/AKT and extracellular signal-related kinase (ERK)/mitogen-activated protein kinase (MAPK) pathways, with PD-L2 inhibiting anti-CD3-induced AKT phosphorylation within minutes and ERK phosphorylation after hours. Analysis of phosphatase activity of Src homology 2 domain-containing tyrosine phosphatase (SHP)-1 and SHP-2 in response to anti-CD3 mAb or anti-CD3 mAb + PD-L2 stimulation revealed that while SHP-1 phosphatase activity is not affected by stimulation, SHP-2 phosphatase activity is significantly increased by anti-CD3 mAb + PD-L2 stimulation. Anti-CD3 mAb + PD-L2 stimulation also increased the level of SHP-2 associated with the PD-1 receptor. These results suggest that catalytically active SHP-2 associated with the PD-1 receptor is involved in modulating T cell function.

Antigens, CD↗
PubMed2002

Charged molecular alloys: synthesis and characterization of the binary anions Pd(7)As(16)(4-) and Pd(2)As(14)(4-).

Pd(PCy(3))(2) (Cy = cyclohexyl) reacts with As(7)(3-) in en/tol solvent mixtures to give Pd(2)As(14)(4-) (2) and Pd(7)As(16)(4-) (4) as the [K(2,2,2-crypt)](+) salts. The anions were characterized by EDX, ESI-MS, and single-crystal X-ray diffraction. Anion 2 formally contains two norbornadiene-like As(7)(5-) groups bound to square-planar Pd(III) centers linked by a Pd-Pd bond (d(Pd)(-)(Pd) = 2.7144(6) A). Anion 4 has a highly distorted capped trigonal prismatic Pd(7) core stabilized by 2 As(5)(1-), 2 As(2)(2-), and 2 As(3-) anions. The 6 Pd(I) ions are in distorted 5-coordinate environments whereas the lone Pd(II) ion is square planar. Complexes 2 and 4 are rare examples of organic-free, homoleptic transition metal anions containing group 15 elements, and they represent an emerging class of charged "molecular alloys".

Journal Article↗
PubMed2005

Probing the molecular orbitals and charge redistribution in organometallic (PP)Pd(XX) complexes. A Pd K-edge XANES study.

Pd K-edge X-ray absorption near-edge spectroscopy (XANES) is used to probe the unoccupied molecular orbitals in bidentate diphosphine Pd complexes. Complexes containing a series of bidentate diphosphine ligands (PP) are examined to study the effect of the ligand bite angle on the charge redistribution in these complexes. Different coordinating moieties (XX) have been used to induce a range of Pd oxidation states. A full interpretation of the Pd K-edge XANES data is presented. The negative second derivative of these XANES data provides direct information on the energy and electronic distribution of the different unoccupied molecular orbitals probed. The charge redistributions within the complexes, as reflected in the effective Pd oxidation state, are indicated by both the intensity of the first edge feature, the "Pd d peak", and the energy of the second edge feature, the "Pd p peak", which can be easily observed in the negative second derivative of the XANES data. Additionally, the changing covalent interaction between the Pd and coordinated moieties via the Pd p orbitals is reflected directly in the energy splitting of the "Pd p" peak. Thus, investigation of these (PP)Pd(XX) complexes, some used as catalysts in organic synthesis, with XANES spectroscopy provides new essential information on their electronic properties. Further, the XANES analysis techniques described in this paper can be applied to investigate the unoccupied molecular orbitals and charge redistributions within a wide range of samples.

Journal Article↗
PubMed2006

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

The past decade has seen a significant increase in the number of potentially tolerogenic therapies for treatment of new-onset diabetes. However, most treatments are antigen nonspecific, and the mechanism for the maintenance of long-term tolerance remains unclear. In this study, we developed an antigen-specific therapy, insulin-coupled antigen-presenting cells, to treat diabetes in nonobese diabetic mice after disease onset. Using this approach, we demonstrate disease remission, inhibition of pathogenic T cell proliferation, decreased cytokine production, and induction of anergy. Moreover, we show that robust long-term tolerance depends on the programmed death 1 (PD-1)-programmed death ligand (PD-L)1 pathway, not the distinct cytotoxic T lymphocyte-associated antigen 4 pathway. Anti-PD-1 and anti-PD-L1, but not anti-PD-L2, reversed tolerance weeks after tolerogenic therapy by promoting antigen-specific T cell proliferation and inflammatory cytokine production directly in infiltrated tissues. PD-1-PD-L1 blockade did not limit T regulatory cell activity, suggesting direct effects on pathogenic T cells. Finally, we describe a critical role for PD-1-PD-L1 in another powerful immunotherapy model using anti-CD3, suggesting that PD-1-PD-L1 interactions form part of a common pathway to selectively maintain tolerance within the target tissues.

Animals↗
PubMed2005

Expression of programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulator ligand on human respiratory tract epithelial cells and regulation by respiratory syncytial virus and type 1 and 2 cytokines.

BACKGROUND: Respiratory syncytial virus (RSV) is associated with wheezing illness, and infections can occur repeatedly throughout life. We hypothesized that RSV infection of respiratory tract epithelial cells up-regulates B7 molecules that regulate memory immune responses and that type 1 and 2 cytokines differentially modulate this induction. METHODS: We used flow-cytometric analysis to investigate programmed death-1 ligand (PD-L) 1, PD-L2, B7-H3, and inducible costimulatory ligand (ICOS-L) expression on tracheal (NCI-H292), bronchial (BEAS-2B), and alveolar (A549) epithelial cells; regulation of this expression by RSV, interferon (IFN)- gamma , and interleukin (IL)-4; and the effects of IFN-gamma and IL-4 on RSV-induced expression of these molecules. RESULTS: B7-H3 was strongly expressed, PD-L1 and ICOS-L were moderately expressed, and PD-L2 was weakly expressed on unstimulated tracheal, bronchial, and alveolar epithelial cells. RSV infection up-regulated PD-L1, PD-L2, and B7-H3 expression on all cells and ICOS-L expression on bronchial and alveolar epithelial cells. IL-4 treatment alone had no effect, whereas IFN-gamma treatment alone increased PD-L1 and PD-L2 expression on all cells and decreased B7-H3 expression on bronchial and alveolar epithelial cells. On RSV-infected alevolar epithelial cells, IFN-gamma treatment increased PD-L1 and PD-L2 expression and decreased B7-H3 and ICOS-L expression, and IL-4 treatment increased PD-L2 and B7-H3 expression and decreased ICOS-L expression. CONCLUSIONS: Respiratory tract epithelial cells express a wide range of B7 molecules. RSV infection increases their expression, and this expression is differentially regulated by IFN-gamma and IL-4. These processes may be involved in decreasing T cell antiviral immune responses to RSV and in RSV-associated wheezing.

Antigens, CD↗
PubMed1998

Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

PD-1, an Ig superfamily member, contains an immunoreceptor tyrosine-based inhibitory motif in the cytoplasmic tail. It is expressed in a minor fraction of CD4-CD8- normal thymocytes and induced in peripheral lymphocytes following activation. To assess the possible roles of PD-1 in the immune responses, PD-1-deficient (PD-1-/-) mice were generated by a gene-targeting strategy. PD-1-4- mice developed and grew normally. Although the thymus was apparently normal, PD-1-/- mice showed moderate but consistent splenomegaly, which reflected the increased cellularity of both lymphoid and myeloid cells. The proliferative response of B cells by anti-IgM antibodies, but not of T cells by an anti-CD3 (145-2C11) mAb in vitro, was augmented in PD-1-/- mice as compared with control littermates. PD-1-/- mice showed increased serum levels of IgG2b, IgA and most strikingly IgG3, while those of IgM and IgG1 were comparable with control mice. Furthermore, PD-1-/- mice exhibited significantly augmented IgG3 anti-DNP antibody response to a type 2 T-independent antigen, DNP-Ficoll, with comparable IgM and IgG1 antibody responses with littermate controls. In the peritoneal cavity, the B-1 cell population in PD-1-/- mice exhibited significantly reduced expression of CD5, a negative regulator of B-1 cell activation, despite a marginal increase in the number of B-1 cells. Thus, PD-1 was suggested to be involved in the negative regulation for particular aspects of B cell proliferation and differentiation including class switching.

Animals↗
PubMed2003

Effluent CA 125 concentration in chronic peritoneal dialysis patients: influence of PD duration, peritoneal transport and PD regimen.

In terms of the integrity of the peritoneal membrane in peritoneal dialysis (PD), the peritoneal mesothelial cells play a pivotal role since its monolayer constitutes the first line of the peritoneal membrane. Cancer antigen 125 (CA 125) is released by peritoneal mesothelial cells and correlates with the mesothelial cell mass in PD. Since its effluent concentration is easy to determine in chronic PD patients, CA 125 serves as an in vivo marker of biocompatibility. We performed a cross-sectional study to investigate the relation between PD duration, peritoneal transport and the PD regimen (CAPD/CCPD) on effluent CA 125 concentration in 22 chronic PD patients. We compared long-term (>6 months) with short-term PD treatment, patients with high small solute transport properties (MTAC >11 ml/min, d/p ratio of creatinine >0.72) to patients with low small solute transport and CAPD with APD patients. A peritoneal equilibration test was performed with 1.36% glucose. Dialysate/plasma (D/P) ratio and mass transfer area coefficient (MTAC) of creatinine were calculated and the 4-hour effluent concentration of CA 125 was determined. CA 125 tended to be lower in the long-term PD patients and also in APD patients, but statistical significance was missing. Effluent CA 125 was significantly increased in patients with an MTAC of creatinine >11 ml/min (40.2 +/- 11.2 vs. 20.7 +/- 1.2 U/ml) and in patients with a d/p ratio of creatinine >0.72 (48.2 +/- 11.0 vs. 21.6 +/- 1.6 U/ml). CA 125 and the d/p ratio of creatinine were positively correlated (r = 0.68). The positive correlation of CA 125 with peritoneal small solute transport especially in the early phase of PD treatment indicates an initial correlation of the mesothelial cell mass with the peritoneal surface area. A direct relation between the CA 125 concentration and peritoneal transport is unlikely. In our study the CA 125 effluent concentration tended to be lower in long-term PD patients and also in APD patients, possibly indicating a cell depletory influence of the conventional PD fluid.

Algorithms↗
PubMed2006

Characterization and catalytic-hydrogenation behavior of SiO2-embedded nanoscopic Pd, Au, and Pd-Au alloy colloids.

Colloids embedded in a silica sol-gel matrix were prepared by using fully alloyed Pd-Au colloids, and pure Pd and Au colloids stabilized with tetraalkylammonium bromide following a modified sol-gel procedure with tetrahydrofuran (THF) as the solvent. Tetraethoxysilicate (TEOS) was used as the precursor for the silica support. The molar composition of the sol was TEOS/THF/H2O/HCl = 1:3.5:4:0.05 for the bimetallic Pd-Au and TEOS/THF/H2O/HCl = 1:4.5:4:0.02 for Pd and Au monometallic systems. After refluxing, the colloid was added as a 4.5 wt % solution in THF for Pd-Au, 10.2 wt % solution in THF for Pd and 8.4 wt % solution in THF for Au at room temperature. The gelation was carried out with vigorous stirring (4 days) under an Ar atmosphere. Following these procedures, bimetallic Pd-Au-SiO2 catalysts with 0.6 and 1 wt % metal, and monometallic Pd- and Au-SiO2 catalysts with 1 wt % metal were prepared. These materials were further treated following four different routes: 1) by simple drying, 2) in which the dried catalysts were calcined in air at 723 K and then reduced at the same temperature, 3) in which they were directly reduced in hydrogen at 723 K, and 4) in which the surfactant was extracted using an ethanol-heptane azeotropic mixture. The catalysts were characterized by nitrogen adsorption-desorption isotherms at 77 K, H2 chemisorption measurements, solid-state 1H, 13C, 29Si-CP/MAS-NMR spectroscopy, powder X-ray diffraction (XRD), small angle X-ray scattering (SAXS), X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), and 197Au Mössbauer spectroscopy. The physical characterization by a combination of these techniques has shown that the size and the structural characteristics of the Pd-Au colloid precursor are preserved when embedded in an SiO2 matrix. Catalytic tests were carried out in selective hydrogenation of 3-hexyn-1-ol, cinnamaldehyde, and styrene. These data showed evidence that alloying Pd with Au in bimetallic colloids leads to enhanced activity and most importantly to improved selectivity. Also, the combination of the two metals resulted in catalysts that were very stable against poisoning, as was evidenced for the hydrogenation of styrene in the presence of thiophene.

Journal Article↗
PubMed2001

Characterization of the active site structure of Pd and Pd-promoted Mo sulfide catalysts by means of XAFS.

Recently, noble metal catalysts are noted as promising candidates for new super-deep-hydrodesulfurization (HDS) catalysts. In this study, we investigated the structure of Pd particles supported on zeolite and Al2O3 under a sulfidation or reduction condition. From EXAFS analysis, it was found for sulfided Pd catalysts that small Pd sulfide clusters are formed without sintering. It was also revealed that no extensive growth of metal Pd particles occurs in Pd/NaY sulfide catalysts even after a treatment with H2 at 673 K. The dispersion of Pd metal particles is improved by H2/H2S treatment. These results indicate that in the presence of H2S, Pd shows high resistance against particle growth. A comparison of the Mo and Pd K-edge EXAFS spectra for MoS(x)/Pd-NaY and Pd-NaY catalysts revealed the existence of Mo-Pd bondings by the addition of Mo sulfide, indicating a direct interaction between Mo and Pd sulfides.

Journal Article↗
PubMed1995

In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency.

PD 138312 and PD 140248 are novel broad-spectrum 7-pyrrolidinyl fluoronaphthyridines with a cyclopropyl or a difluorophenyl substitution at the 1 positions, respectively. They have been demonstrated to have excellent in vitro activity against gram-positive organisms. These compounds were evaluated for their in vivo potencies against acute systemic infections in mice and in a mouse pneumococcal pneumonia model. They were very effective by both the oral and subcutaneous routes of administration. Most remarkable were their comparative median protective values against methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. In general, these compounds were 28- to 100-fold more active than ciprofloxacin against these clinically significant organisms when the drugs were given orally and 10- to 38-fold more active when the drugs were given parenterally. Average ratios of drug concentrations in mice after drug administration by the oral route to that after administration by the subcutaneous route indicate 34 to 44% greater bioavailabilities of PD 138312 and PD 140248 compared with that of ciprofloxacin. In a multidose pneumococcal mouse pneumonia model these new quinolones were extremely effective, with median curative doses of 2 to 2.8 mg/kg of body weight per dose. Ciprofloxacin was ineffective (median curative dose, >100 mg/kg per dose) in this model. Comparative pharmacokinetic studies in mice revealed a relative superiority of PD 140248. Peak levels of PD 140248 in blood after the administration of a single oral 50-mg/kg dose were twice those of PD 138312 and ciprofloxacin, with PD 140248 having a substantially longer half-life. These results indicate that PD 138312 and PD 140248 have excellent therapeutic potential against clinically important gram-positive pathogens when the drugs are administered both orally and parenterally.

Animals↗
PubMed2004

Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.

BACKGROUND: Programmed death-1 (PD-1), a member of the CD28 family, has been identified. PD-1 is involved in the negative regulation of some immune responses. We evaluated the role of PD-ligand 1 (PD-L1) in graft arterial disease (GAD) of cardiac allografts and in smooth muscle cells (SMCs). METHODS AND RESULTS: C57BL/6 murine hearts were transplanted into B6.C-H2 KhEg mice for examination of GAD. PD-L1 was expressed in SMCs of the thickened intima in the graft coronary arteries, and administration of anti-PD-L1 monoclonal antibody (mAb) enhanced the progression of GAD (luminal occlusion: 55+/-5.0% versus 9.8+/-4.3%, P<0.05). The expressions of interferon gamma (IFN-gamma) and tumor necrosis factor alpha of cardiac allografts were upregulated in response to anti-PD-L1 mAb treatment. In vitro, PD-L1 expression was induced in SMCs in response to IFN-gamma stimulation. Sensitized splenocytes increased SMC proliferation, and anti-PD-L1 mAb in combination with IFN-gamma stimulation increased this proliferation. CONCLUSIONS: The PD-L1 pathway regulates both the proliferation of SMCs and GAD. Thus, control of this interaction is a promising strategy for suppression of GAD.

Animals↗
PubMed2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

BACKGROUND: Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizing anti-GDF-15 antibody, plus the anti-PD-1 antibody nivolumab (V+N) was evaluated in the first-in-human phase 1/2a GDFATHER-01 trial in heavily pretreated participants with locally advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC), urothelial carcinoma (UC), or hepatocellular carcinoma (HCC), stringently defined as anti-PD-1/PD-L1-relapsed/refractory, and showed encouraging objective responses. This analysis reports long-term follow-up of these three phase 2 expansion cohorts of the GDFATHER-01 trial. METHODS: Seventy-seven participants with nsq NSCLC (N=22), UC (N=27), and HCC (N=28) received visugromab (10 mg/kg) plus nivolumab (240 mg) every two weeks until disease progression or unacceptable toxicity. RESULTS: Objective response rates (RECIST v1.1) were 18.2% for nsq NSCLC (4/22; 95%CI 5.2-40.3), 18.5% for UC (5/27; 95%CI 6.3-38.1), and 14.3% for HCC (4/28; 95%CI 4.0-32.7). Median duration of response (DoR) was 32.2 months (95%CI 5.5-38.0), 28.8 months (95%CI 7.4-39.4), and 19.4 months (95%CI 5.8-39.7; with protracted recruitment), respectively, with 7/13 responses (53.8%) ongoing. Confirmed complete response or complete metabolic response (CR or CMR) among responders was 61.5% (8/13), with 7/8 ongoing. In addition, 46.2% (6/13) of responders achieved a deeper response on V+N per RECIST v1.1 than with the prior anti-PD-(L)1 therapy; median DoR on V+N was 28.8 months (95%CI 7.4-38.0) versus 12.0 months (95%CI 8.0-24.0) on initial anti-PD-1/PD-L1 treatment. V+N was generally well tolerated. CONCLUSIONS: In heavily pretreated, advanced/metastatic participants with nsq NSCLC, UC, or HCC who were anti-PD-1/PD-L1-relapsed/refractory, V+N achieved deep and durable objective responses. The observed DoR, depth of response, and CR+CMR rate among responders exceeded those reported for their initial anti-PD-1/PD-L1 therapy. These findings suggest that GDF-15 blockade with visugromab can overcome resistance and enhance the magnitude and durability of anti-PD-1/PD-L1 responses, and warrant further exploration in randomized trials. REGISTRY: ClinicalTrials.gov, TRN: NCT04725474, Registration date: 25 January 2021; EudraCT, TRN: 2020-002103-19, Registration date 16 Dec 2020.

Humans↗
PubMed1985

G-6-PD Jalisco and G-6-PD Morelia: two new Mexican variants.

Two new G-6-PD variants designated G-6-PD Jalisco and G-6-PD Morelia were identified in two unrelated Mexican families. An additional G-6-PD variant was found in each family: G-6-PD Trinacria and G-6-PD A-. In both families compound heterozygotes were identified. G-6-PD Jalisco and G-6-PD Morelia belong to Classes 3 and 4, respectively. G-6-PD Morelia is the first variant from its class with a high Km for NADP and a low Ki for NADPH.

Adult↗
PubMed1986

Metal anthracycline complexes as a new class of anthracycline derivatives. Pd(II)-adriamycin and Pd(II)-daunorubicin complexes: physicochemical characteristics and antitumor activity.

Pd(II) complexes of two anthracyclines, adriamycin and daunorubicin, have been studied. Using potentiometric absorption, fluorescence, and circular dichroism measurements, we have shown that adriamycin can form two complexes with Pd(II). The first complex (I) involves two molecules of drug per Pd(II) ion; one of the molecules is chelated to Pd(II) through the carbonyl oxygen on C12 and the phenolate oxygen on C11, and the other one is bound to Pd(II) through the nitrogen of the amino sugar. This complexation induces a stacking of the two molecules of drug. In the second complex (II), two Pd(II) ions are bound to two molecules of drug (A1 and A2). One Pd(II) is bound to the oxygen on the carbons C11 and C12 of molecule A1 and the amino sugar of molecule A2 whereas the second Pd(II) ion is bound to the oxygen on C11 and C12 of molecule A2 and the amino sugar of molecule A1. The same complexes are formed between Pd(II) and daunorubicin. The stability constant for complex II is beta = (1.3 +/- 0.5) X 10(22). Interaction with DNA has been studied, showing that almost no modification of the complex occurred. This complex displays antitumor activity against P-388 leukemia that compares with that of the free drug. Complex II, unlike adriamycin, does not catalyze the flow of electrons from NADH to molecular oxygen through NADH dehydrogenase.

Animals↗
PubMed1997

Synthesis, Molecular Structure, and Reactivity of the Tetranuclear Complex [NBu(4)](2)[Pd(4)(&mgr;-PPh(2))(2)(&mgr;-Cl)(4)(C(6)F(5))(4)]. Molecular Structure of [Pd(2)(&mgr;-PPh(2))(C(6)F(5))(2)(bipy)(2)]ClO(4).C(6)H(14).

Anionic tetranuclear complexes with the molecular formula [NBu(4)](2)[Pd(4)(&mgr;-PPh(2))(2)(&mgr;-X)(4)(C(6)F(5))(4)] [X = Cl (1), Br (2)] were obtained by reaction of [NBu(4)](2)[Pd(2)(&mgr;-PPh(2))(2)(C(6)F(5))(4)] and PdCl(2) (or K(2)[PdCl(4)]) in acetone, followed by reaction with KBr for 2. The reactions of 1 with neutral monodentate (L) or bidentate (L-L) ligands afford the dinuclear derivatives [Pd(2)(&mgr;-PPh(2))(&mgr;-Cl)(C(6)F(5))(2)L(2)] [L = PPh(3) (3), py (4)] or [Pd(2)(&mgr;-PPh(2))(C(6)F(5))(2)(L-L)(2)](n)() [n = 1-, L-L = acac (6); n = 1+, L-L = bipy (7) or phen (8)]. The structures of complexes 1 and 7 were determined by single-crystal X-ray diffraction studies. The bis(acetone) solvate of complex 1, [NBu(4)](2)[Pd(4)(&mgr;-PPh(2))(2)(&mgr;-Cl)(4)(C(6)F(5))(4)].2C(3)H(6)O, crystallizes in the monoclinic system, space group P2(1)/c, with a = 11.679(5) Å, b = 16.552(7) Å, c = 23.868(8) Å, beta = 101.10(3) degrees, V = 4527.6(15) Å(3), and Z = 2. The central core of the anion has the shape of a rectangle with the four Pd atoms in the corners. The hexane solvate of complex 7, [Pd(2)(&mgr;-PPh(2))(C(6)F(5))(2)(bipy)(2)][ClO(4)].C(6)H(14), crystallizes in the monoclinic system, space group P2(1)/n, with a = 16.214(3) Å, b = 10.311(2) Å, c = 28.380(6) Å, beta = 100.82(3) degrees, V = 4660(2) Å(3), and Z = 4. In both complexes, the long Pd.Pd distances (>3.1 Å) clearly point to the absence of any Pd-Pd interaction.

Journal Article↗
PubMed1998

Synthesis and Characterization of Palladium(II) Complexes with New Polydentate Nitrogen Ligands. Dynamic Behavior Involving Pd-N Bond Rupture. X-ray Molecular Structure of [{Pd(eta(3)-C(4)H(7))}(2)(Me-BPzTO)](4-MeC(6)H(4)SO(3)) [Me-BPzTO = 4,6-Bis(4-methylpyrazol-1-yl)-1,3,5-triazin-2-olate].

The ligands 2,4,6-tris(4-methylpyrazol-1-yl)-1,3,5-triazine (Me-TPzT), 2,4,6-tris(4-bromopyrazol-1-yl)-1,3,5-triazine (Br-TPzT), and 2-methoxy-4,6-bis(4-methylpyrazol-1-yl)-1,3,5-triazine (Me-BPzTOMe) have been synthesized and their reactions with some palladium derivatives explored. The palladium fragment [Pd(eta(3)-2-Me-C(3)H(4))(S)(2)](+), S = acetone, reacts in acetone with Me-TPzT or Br-TPzT in a 3:1 molar ratio to generate new complexes in which two allylpalladium fragments are present and the TPzT ligands have been partially hydrolyzed: [{Pd(eta(3)-C(4)H(7))}(2)(X-BPzTO)]A, X-BPzTO = 4,6-bis[4-methyl(or bromo)pyrazol-1-yl]-1,3,5-triazin-2-olate (X = Me, A = BF(4), 1; A = PF(6), 2; A = CF(3)SO(3), 3; A = p-MeC(6)H(4)SO(3), 4; X = Br, A = CF(3)SO(3), 5). When the ligand Me-BPzTOMe is made to react with only 1 equiv of the palladium solvate, compound 6, [Pd(eta(3)-2-Me-C(3)H(4))(Me-BPzTOMe)]CF(3)SO(3), is isolated. Reaction of 6 with another 1 equiv of the palladium derivative leads to 3. The intermediate 7, [{Pd(eta(3)-2-Me-C(3)H(4))}(2)(Me-BPzTOMe)]CF(3)SO(3), has been isolated as an almost pure compound. The reaction of Me-BPzTOMe with 1 equiv of [Pd(C(6)F(5))(2)(cod)] (cod = 1,5-cyclooctadiene) leads to the complex [Pd(C(6)F(5))(2)(Me-BPzTOMe)], 8. Attention has been focused on the dynamic behavior, related with metallotropic phenomena, of the new complexes. (1)H NMR variable-temperature studies of complexes 1, 6, and 8 have been carried out. For 8, only one static species is observed, while, for 1 and 6, two isomers are detected at low temperature. Different DeltaG(c)() activation energies at the coalescence temperature have been determined and are ascribed to processes implying Pd-N bond ruptures. For 6, two different barriers are detected, corresponding to Pd-N(triazine) or Pd-N(pyrazole) bond ruptures. From the DeltaG(c)() data, it is concluded that the main driving force of the hydrolysis process is the formation of a better coordinating ligand. The molecular structure of 4 has been determined by X-ray diffraction. The meso isomer, in which the two C-Me axes of the allylic groups are oriented in the same direction, is found in the solid state.

Journal Article↗